SML0492
Zanamivir
≥98% (HPLC), Influenza viral neuraminidase inhibitor, powder
别名:
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H20N4O7
化学文摘社编号:
分子量:
332.31
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Zanamivir, ≥98% (HPLC)
SMILES string
CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O
InChI
1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
InChI key
ARAIBEBZBOPLMB-UFGQHTETSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +30 to +40°, c = 1 in H2O
color
white to beige
solubility
H2O: 10 mg/mL, clear
storage temp.
room temp
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
Zanamivir has been used:
- as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
- as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
- as an antiviral to study its effects on influenza B virus by plaque reduction assay
Biochem/physiol Actions
Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.
Zanamivir is an influenza viral neuraminidase inhibitor.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Celia Jakob et al.
Nucleic acids research, 51(12), 6479-6494 (2023-05-24)
A fundamental step in the influenza A virus (IAV) replication cycle is the coordinated packaging of eight distinct genomic RNA segments (i.e. vRNAs) into a viral particle. Although this process is thought to be controlled by specific vRNA-vRNA interactions between
Erhard van der Vries et al.
PLoS pathogens, 8(9), e1002914-e1002914 (2012-10-03)
Two classes of antiviral drugs, neuraminidase inhibitors and adamantanes, are approved for prophylaxis and therapy against influenza virus infections. A major concern is that antiviral resistant viruses emerge and spread in the human population. The 2009 pandemic H1N1 virus is
Zanamivir
Waghorn S L and Goa K L
Drugs, 55(5), 721-725 (1998)
Emi Takashita et al.
Antimicrobial agents and chemotherapy, 59(5), 2607-2617 (2015-02-19)
Between September 2013 and July 2014, 2,482 influenza 2009 pandemic A(H1N1) [A(H1N1)pdm09] viruses were screened in Japan for the H275Y substitution in their neuraminidase (NA) protein, which confers cross-resistance to oseltamivir and peramivir. We found that a large cluster of
Mila B Ortigoza et al.
mBio, 15(2), e0220323-e0220323 (2024-01-11)
The ongoing transmission of influenza A viruses (IAV) for the past century continues to be a burden to humans. IAV binds terminal sialic acids (SA) of sugar molecules present within the upper respiratory tract (URT) in order to successfully infect
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持